Medical treatment of Marfan syndrome: A time for change

Heart

Volumn 94, Issue 4, 2008, Pages 414-421

  Williams, A ^a   Davies, S ^b   Stuart, A G ^c   Wilson, D G ^b   Fraser, A G ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

^c BRISTOL ROYAL HOSPITAL FOR CHILDREN   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2 ISOPROPYLIDENEHYDRAZONO 4 OXO 5 THIAZOLIDINYLACETANILIDE; ALAGEBRIUM; ALDOSTERONE ANTAGONIST; AMINOGUANIDINE; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXYCYCLINE; ENALAPRIL; IRBESARTAN; LOSARTAN; MATRIX METALLOPROTEINASE INHIBITOR; METOPROLOL; NIFEDIPINE; NITRIC ACID DERIVATIVE; ORGANIC NITRATE; PERINDOPRIL; PLACEBO; PROPRANOLOL; PYRIDOXAMINE; RESERPINE; TETRACYCLINE; TISSUE INHIBITOR OF METALLOPROTEINASE; UNINDEXED DRUG; UROKINASE; VERAPAMIL;

AORTA DISSECTION; AORTA RUPTURE; CLINICAL FEATURE; CLINICAL TRIAL; DISSECTING ANEURYSM; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG HALF LIFE; DRUG MECHANISM; HUMAN; MARFAN SYNDROME; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; UNSPECIFIED SIDE EFFECT;

ADRENERGIC BETA-ANTAGONISTS; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; CARDIOVASCULAR AGENTS; HUMANS; LOSARTAN; MARFAN SYNDROME;

EID: 41249098667     PISSN: 13556037     EISSN: None     Source Type: Journal    
DOI: 10.1136/hrt.2006.109454     Document Type: Review

References (54)

1. Marfan AB. Un cas de deformation congenitale des quatre members, plus prononcee aux extremities, caracterisee par l'allongemont des os avec un certain degree d'amincissement. Bull Mem Soc Med Hop Paris 1896;13:220-6.
2. Dietz HC, Pyeritz RE. Mutations in human gene for fibrillin-1 in the Marfan syndrome and related disorders. Hum Mol Genet 1995;4:1799-809.
3. Gray JR, Bridges AB, West RR, et al. Life expectancy in British Marfan syndrome populations. Clin Genet 1998;54:124-8.
4. Government Actuaries Department. http://www.gad.gov.uk/ (accessed 17 February 2008).
5. Silverman DI, Burton BS, Gray J, et al. Life expectancy in the Marfan syndrome. Am J Cardiol 1995;75:157-60.
6. Januzzi JL, Marayati F, Mehta RH, et al. Comparison of aortic dissection in patients with and without Marfan's syndrome. Am J Cardiol 2004;94:400-2.
7. UMD website. http://www.umd.be (accessed 11 February 2008).
8. Mizuguchi T, Collod-Beroud G, Akiyama T, et al. Heterozygous TGFBR2 mutations in Marfan syndrome. Nat Genet 2004;36:855-60.
9. Beals RK, Hecht F. Congenital contractural arachnodactyly. A heritable disorder of connective tissue. J Bone Joint Surg Am 1971;53:987-93.
10. Hirata K, Triposkiadis F, Sparks E, et al. The Marfan syndrome: abnormal aortic elastic properties. J Am Coll Cardiol 1991;18:57-63.
11. Bridges AB, Gray JR, McLaren M, et al. Endothelial cell and platelet function in Marfan syndrome. Endothelium 1993;1:203-6.
12. Wilson DG, Bellamy MF, Ramsey MW, et al. Endothelial function in Marfan syndrome: selective impairment of flow-mediated vasodilatation. Circulation 1999;99:909-15.
13. Neptune ER, Frischmeyer PA, Arking DE, et al. Dysregulation of TGF-β1 activation contributes to pathogenesis in Marfan syndrome. Nat Genet 2003;33:407-11.
14. Ng CM, Cheng A, Myers LA, et al. TGF-β1-dependent pathogenesis of mitral valve prolapse in a mouse model of Marfan syndrome. J Clin Invest 2004;114:1586-92.
15. Habashi JP, Judge DP, Holm TM, et al. Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome. Science 2006;312:117-21.
16. Ringer RK. Influence of reserpine on early growth, blood pressure and dissecting aneurysms in turkeys. CIBA Summit, NJ 1959:21-28.
17. Wheat MW, Palmer RF, Bartley TD, et al. Treatment of dissecting aneurysms of the aorta without surgery. J Thorac Cardiovasc Surg 1965;50:364-73.
18. Halpern BL, Char F, Murdoch JL, et al. A prospectus on the prevention of aortic rupture in the Marfan syndrome with data on survivorship without treatment. Johns Hopkins Med J 1971;129:123-9.
19. Ose L, McKusick VA. Prophylactic use of propranolol in the Marfan syndrome to prevent aortic dissection. Birth Defects Orig Artic Ser 1977;13:163-9.
20. Shores J, Berger KR, Murphy E, et al. Progression of aortic dilatation and the benefit of long-term beta-adrenergic blockade in Marfan syndrome. N Engl J Med 1994;330:1335-41.
21. Cholley BP, Shroff SG, Sandelski J, et al. Aortic and other vascular disease: differential effects of chronic oral antihypertensive therapies on systemic arterial circulation and ventricular energetics in African-American patients. Circulation 1995;91:1052-62.
22. London GM, Asmar RG, O'Rourke MF, et al. Mechanism(s) of selective systolic blood pressure reduction after a low-dose combination of perindopril/indapamide in hypertensive subjects: comparison with atenolol. J Am Coll Cardiol 2004;43:92-9.
23. Hirata K, Vlachopoulos C, Adji A, et al. Benefits from angiotensin-converting enzyme inhibitor 'beyond blood pressure lowering': beyond blood pressure or beyond the brachial artery? J Hypertens 2005;23:551-6.
24. Dhakam Z, McEniery CM, Yasmin J, et al. Atenolol and eprosartan: differential effects on central blood pressure and aortic pulse wave velocity. Am J Hypertens 2006;19:214-9.
25. Salim MA, Alpert BS, Ward JC, et al. Effect of beta-adrenergic blockade on aortic root dilatation in the Marfan syndrome. Am J Cardiol 1994;74:629-32.
26. Joannides R, Richard V, Moore N, et al. Influence of sympathetic tone on mechanical properties of muscular arteries in humans. Am J Physiol 1995;268:H794-801.
27. Haouzi A, Berglund H, Pelikan PCD, et al. Heterogeneous aortic response to acute beta-adrenergic blockade in Marfan syndrome. Am Heart J 1997;133:60-3.
28. Groenink M, de Roos A, Mulder BJ, et al. Changes in aortic distensibility and pulse wave velocity assessed with magnetic resonance imaging following beta-blocker therapy in the Marfan syndrome. Am J Cardiol 1998;82:203-8.
29. Reed CM, Fox ME, Alpert BS. Aortic biomechanical properties in paediatric patients with the Marfan syndrome, and the effects of atenolol. Am J Cardiol 1993;71:606-8.
30. Yin FC, Brin KP, Ting CT, et al. Arterial haemodynamic indexes in Marfan's syndrome. Circulation 1989;79:854-62.
31. Rios AS, Silber EN, Bavishi N, et al. Effect of long-term beta-blockade on aortic root compliance in patients with Marfan syndrome. Am Heart J 1999;137:1057-61.
32. Reed CM, Alpert BS. Assessment of ventricular performance after chronic beta-adrenergic blockade in the Marfan syndrome. Am J Cardiol 1992;70:541-2.
33. Robinson RF, Nahata MC, Batisky DL, et al. Pharmacologic treatment of chronic paediatric hypertension. Paediatr Drugs 2005;7:27-40.
34. Rossi-Foulkes R, Roman MJ, Rosen SE, et al. Phenotypic features and impact of beta blocker or calcium antagonist therapy on aortic lumen size in the Marfan syndrome. Am J Cardiol 1999;83:1364-8.
35. Yetman AT, Bornemeier RA, McCrindle BW. A comparison of beta-blockers and angiotensin converting enzyme inhibitors on aortic elastic properties, aortic growth, and left ventricular size and function in Marfan patients. J Am Coll Cardiol 2003;(Suppl):492A.
36. Lacourciere Y, Beliveau R, Conter HS, et al. Effects of perindopril on elastic and structural properties of large arteries in essential hypertension. Can J Cardiol 2004;20:795-9.
37. Nagashima H, Sakomura Y, Aoka Y, et al. Angiotensin 2 type receptor mediated vascular smooth muscle cell apoptosis in cystic medial degeneration associated with Marfan's syndrome. Circulation 2001;104(Suppl I):I-282-7.
38. Nagashima H, Uto K, Sakomura Y, et al. An angiotensin-converting enzyme inhibitor, not an angiotensin 2 type 1 receptor blocker, prevents β-aminopropionitrile monofumarate-induced aortic dissection in rats. J Vasc Surg 2002;36:818-23.
39. Yetman AT, Bornemeier RA, McCrindle BW. Usefulness of enalapril versus propranolol or atenolol for the prevention of aortic dilation in patients with the Marfan syndrome. Am J Cardiol 2005;95:1125-7.
40. Schieffer B, Bunte C, Witte J, et al. Comparative effects of angiotensin-1 antagonism and angiotensin-converting enzyme inhibition on markers of inflammation and platelet aggregation in patients with coronary artery disease. J Am Coll Cardiol 2004;44:362-8.
41. Dzau VJ. Significance of the vascular renin-angiotensin pathway. Hypertension 1986;8:553-9.
42. Lavoie P, Robitaille G, Agharazii M, et al. Neutralisation of transforming growth factor-beta attenuates hypertension and prevents renal injury in uraemic rats. J Hypertens 2005;23:1895-903.
43. Lim D-S, Lutucuta S, Bachireddy P, et al. Angiotensin II blockade reverses myocardial fibrosis in a transgenic mouse model of human hypertrophic cardiomyopathy. Circulation 2001;103:789-91.
44. National Marfan foundation. http://www.marfan.org/nmf (accessed 11 February 2008).
45. Current controlled trials. The effects of angiotensin 2 blockade and long acting nitrates on arterial stiffness in patients with Marfan syndrome. A placebo controlled study (NITRATES)). (ISRCTN28168217) Available at http://www.controlled-trials.com (accessed 11 February 2008).
46. Benjamin IJ. Matrix metalloproteinases: from biology to therapeutic strategies in cardiovascular disease. J Invest Med 2001;49:381-97.
47. Segura AM, Luna RE, Horiba K, et al. Immunohistochemistry of matrix metalloproteinases and their inhibitors in thoracic aortic aneurysms and aortic valves of patients with Marfan's syndrome. Circulation 1998;98:II331-7.
48. Thompson RW, Baxter BT. MMP inhibition in abdominal aortic aneurysms. Rationale for a prospective, randomised clinical trial. Ann N Y Acad Sci 1999;878:159-78.
49. Curci JA, Mao D, Bohner DG, et al. Preoperative treatment with doxycycline reduces aortic wall expression and activation of matrix metalloproteinases in patients with abdominal aortic aneurysms. J Vasc Surg 2000;31:325-42.
50. Zieman SJ, Kass DA. Advanced glycation endproduct crosslinking in the cardiovascular system. Drugs 2004;64:459-70.
51. Vaitkevicius PV, Lane M, Spurgeon H, et al. A cross-link breaker has sustained effects on arterial and ventricular properties in older rhesus monkeys. Proc Natl Acad Sci USA 2001;98:1171-5.
52. Kass DA, Shapiro EP, Kawaguchi M, et al. Improved arterial compliance by a novel advanced glycation end-product crosslink breaker. Circulation 2001;104:1464-70.
53. Giusti B, Porciani MC, Brunelli T, et al. Phenotypic variability of cardiovascular manifestations in Marfan syndrome. Eur Heart J 2003;24:2038-45.
54. De Paepe A, Devereux RB, Dietz HC, et al. Revised criteria for the Marfan syndrome. Am J Med Genet 1996;62:417-26.